Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca M. Marin, Jann N. Sarkaria, Kendra A. Porath et al.|Neuro-Oncology|2021Cited by 81
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain BarrierMinjee Kim, Jann N. Sarkaria, J. Daniel et al.|Molecular Cancer Therapeutics|2018Cited by 40
The impact of adding optical coherence tomography in MS diagnostic criteria on the classification of tumefactive demyelinationFiorella S. Guido, W. Oliver Tobin, B. Mark Keegan et al.|Journal of the Neurological Sciences|2026Cited by 1
Data from Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain BarrierMinjee Kim, Jann N. Sarkaria, J. Daniel et al.|Unknown|2023Cited by 0